12 Results for "

SNU-5

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "SNU-5" in MCE Product Catalog:

27
27 Publications Verification
Cat. No.: HY-13404
CAS No.: 1029712-80-8
Purity:  99.75%
Synonyms: INC280; INCB28060
Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .
loading...
    loading...
27
27 Publications Verification
Cat. No.: HY-13404C
CAS No.: 1865733-40-9
Purity:  99.78%
Synonyms: INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate
Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .
loading...
    loading...
27
27 Publications Verification
Cat. No.: HY-13404A
CAS No.: 1197376-85-4
Synonyms: INC280 dihydrochloride; INCB28060 dihydrochloride
Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .
loading...
    loading...
27
27 Publications Verification
Cat. No.: HY-13404B
CAS No.: 1029714-89-3
Purity:  99.60%
Synonyms: INC280 hydrochloride; INCB-28060 hydrochloride
Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18696
CAS No.: 1173699-31-4
Research Areas:  

Cancer

AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC50 values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis .
loading...
    loading...
Cat. No.: HY-P99192
CAS No.: 1365287-97-3
Synonyms: LY2875358

Target:  

c-Met/HGFR

Research Areas:  

Cancer

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
loading...
    loading...
Cat. No.: HY-16446
CAS No.: 1116743-46-4
Research Areas:  

Cancer

SAR125844 is a potent, selective, and ATP-competitive MET kinase inhibitor with the value of IC50 is 4.2 nM and Ki is 2.8 nM. SAR125844 has antitumor activity and can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-147259
CAS No.: 1637658-98-0
Purity:  98.28%
Target:  

c-Met/HGFR

Research Areas:  

Cancer

Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-13404R
CAS No.: 1029712-80-8
Synonyms: INC280 (Standard); INCB28060 (Standard)
Research Areas:  

Cancer

Capmatinib (Standard) is the analytical standard of Capmatinib. This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .
loading...
    loading...
Cat. No.: HY-165284
CAS No.: 1370652-56-4
Research Areas:  

Cancer

CM-118 is a potent and selective c-Met and ALK inhibitor. CM-118 inhibits the HGF-induced c-Met phosphorylation. CM-118 inhibits phosphorylation of ALK, EML4-ALKv1, ALK F1174L, and EMl4-ALKv1 L1196M, with respective IC50 values 0.92, 1.25, 1.9, and 3.5 μM. CM-118 exhibits anticancer activity against cancers dependent on the c-Met or ALK oncogenic pathways .
loading...
    loading...
Cat. No.: HY-168268
CAS No.: 1635406-97-1
Target:  

c-Met/HGFR

Research Areas:  

Cancer

c-Met-IN-26 (compound 1-170) is a potent inhibitor of c-Met, with the IC50 of 1.6 nM. c-Met-IN-26 palys an important role in cancer research .
loading...
    loading...
Cat. No.: HY-13404CR
CAS No.: 1865733-40-9
Synonyms: INC280 dihydrochloride hydrate (Standard); INCB-28060 dihydrochloride hydrate (Standard)
Research Areas:  

Cancer

Capmatinib (dihydrochloride hydrate) (Standard) is the analytical standard of Capmatinib (dihydrochloride hydrate). This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .
loading...
    loading...
  • 1